Tarsus Pharmaceuticals (TARS) Stock Highlights

46.58 | -0.66%

2024-11-21 03:02:23

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The companys lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.

Statistics

Range Today

45.73 47.37

Volume Today 356.4K

Range 1 Year

15.6 52.99

Volume 1 Year 182.03M

Range 3 Year

10.8 52.99

Volume 3 Year 277.97M

Range 10 Year

10.8 63.69

Volume 10 Year 295.47M

Highlights

Market Capitalization 1.88B (small)

Floating Shares 28.83M

Current Price 46.58

Price To Earnings -10.04

Price To Revenue 19.55

Price To Book 7.45

Earnings Per Share -4.71

Payout Ratio 0%

Performance

Latest -0.66%

1 Month +27.41%

3 Months +76.17%

6 Months +21.56%

1 Year +152.6%

3 Years +86.92%

5 Years +187.53%

10 Years +187.53%

Benchmarks

Market Capitalization

109 / 368

Gross Profits

169 / 278

Total Revenue

172 / 300

Total Rank

281 / 368

Free Cashflow

231 / 352

Performance 5 years

49 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.